Streamlined and Sponsor-Friendly: What China’s Amended Drug Regulations Mean for Pharma Companies
On January 27, 2026, China’s State Council published the amended Implementing Regulations of the Drug Administration Law, which will take effect on May 15, 2026. These regulations are a significant…
Read the full articleYou might also wanna read
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·26d ago
DSCSA compliance and 2024/2025 implementation timeline
The US Congress enacted the Drug Supply Chain Security Act (DSCSA) in late November 2013, with the aim of providing additional oversight of
What the Updated 1260H List Means for Biotechnology Procurement
On June 8, 2026, the Department of War (“DoW”) published its updated list of “Chinese military companies” operating in the United States (“1
China's AI Content Labeling Law Enforced September 2025
China's new AI labeling law, effective September 2025, mandates visible and hidden labels for AI-generated content to curb misinformation.
China's Rise in Global Clinical Trials: Regulatory Reforms and US Competitiveness
Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the
pca.st·19d ago
China's Rise in Global Clinical Trials: Regulatory Reforms and US Competitiveness
Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the
pocketcasts.com·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.